Search results for "single"

showing 10 items of 4920 documents

Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2…

2018

69 Background: HER2 is overexpressed in many solid tumors and is a validated therapeutic target. GBR 1302 is a HER2xCD3 bispecific antibody engineered (using Glenmark’s BEAT® platform) to direct T-cells to HER2-expressing tumor cells. GBR1302-101 (NCT02829372) is an ongoing, multicenter, open-label, first-in-human study of GBR 1302 in subjects with HER2-positive cancers to evaluate the safety, tolerability, and preliminary efficacy of GBR 1302, and to elucidate the mechanism(s) by which it redirects T-cells to tumor and enhances cytolytic activity of cytotoxic T-cells. Methods: Adults with progressive HER2-positive solid tumors with no available standard or curative treatment receive intra…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBispecific antibodybusiness.industryT cellPhase i study03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesisInternal medicinePharmacodynamicsmedicineBiomarker (medicine)Cytotoxic T cellSingle agentbusinessJournal of Clinical Oncology
researchProduct

Genetically Determined Height and Risk of Non-hodgkin Lymphoma

2020

Although the evidence is not consistent, epidemiologic studies have suggested that taller adult height may be associated with an increased risk of some non-Hodgkin lymphoma (NHL) subtypes. Height is largely determined by genetic factors, but how these genetic factors may contribute to NHL risk is unknown. We investigated the relationship between genetic determinants of height and NHL risk using data from eight genome-wide association studies (GWAS) comprising 10,629 NHL cases, including 3,857 diffuse large B-cell lymphoma (DLBCL), 2,847 follicular lymphoma (FL), 3,100 chronic lymphocytic leukemia (CLL), and 825 marginal zone lymphoma (MZL) cases, and 9,505 controls of European ancestry. We …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyChronic lymphocytic leukemiaFollicular lymphomadiffuse large B-cell lymphomaSingle-nucleotide polymorphismGenome-wide association studylcsh:RC254-28203 medical and health sciences0302 clinical medicinefollicular lymphomaimmune system diseasesInternal medicinehemic and lymphatic diseasesGeneticsMedicineLeucèmia limfocítica crònicageneticsOriginal ResearchGenetic associationCancer och onkologibusiness.industrynon-Hodgkin lymphomaOdds ratiomedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmarginal zone lymphomaLymphomaMalaltia de Hodgkin030104 developmental biologyOncologyCancer and Oncology030220 oncology & carcinogenesispolygenic risk scorediffuse large B-celllymphomachronic lymphocytic leukemiaChronic lymphocytic leukemiaHodgkin's diseasegeneticbusinessDiffuse large B-cell lymphomaGenèticaheightFrontiers in Oncology
researchProduct

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the Europe…

2020

Background Irreversible sensorineural hearing loss is a common side effect of platinum treatment with the potential to significantly impair the neurocognitive, social and educational development of childhood cancer survivors. Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in the FDA drug label and a pharmacogenetic guideline. The aim of this cross-sectional cohort study was to confirm the genetic associations in a large pan-European population and to evaluate the diagnostic accuracy of the genetic…

0301 basic medicineOncologyMaleCancer ResearchCandidate genePharmacogenomic VariantsCancer survivorsCHILDRENAnti-neoplastic drugsVARIANTSOCT2Carboplatin0302 clinical medicineHearingRisk FactorsNeoplasmsTPMTHearing / drug effectsProspective StudiesAge of OnsetChild610 Medicine & healthPREDICTORSmedia_commonHearing Loss Sensorineural / physiopathologyeducation.field_of_studyddc:618Thiopurine methyltransferasebiologycarboplatin [Cisplatin]Neoplasms / drug therapyOrganic Cation Transporter 2EuropeOncologyCisplatin: carboplatinCisplatin / adverse effects030220 oncology & carcinogenesisChild PreschoolOrganic Cation Transporter 2 / geneticsFemaleSENSITIVITYChildhood cancer360 Social problems & social servicesCohort studyDrug-induced ototoxicitymedicine.medical_specialtyINDUCED HEARING-LOSSAdolescentMulticenter cohort studyHearing Loss SensorineuralPopulationAdverse drug reactionAntineoplastic AgentsPolymorphism Single NucleotideRisk AssessmentHearing Loss Sensorineural / chemically inducedCarboplatin / adverse effects03 medical and health sciencesACYP2OtotoxicitySDG 3 - Good Health and Well-beingInternal medicinemedicineGenetic predispositionmedia_common.cataloged_instanceHumansGenetic Predisposition to DiseaseCISPLATIN-INDUCED OTOTOXICITYEuropean unioneducationGenetic Association StudiesGenetic associationRetrospective Studiesbusiness.industryAntineoplastic Agents / adverse effectsInfant NewbornInfantOdds ratioGuidelinemedicine.diseaseOtotoxicityCOMTPharmacogenomic Testing030104 developmental biologyCross-Sectional StudiesPharmacogeneticsbiology.proteinGenetic markersHearing Loss Sensorineural / geneticsCisplatinbusinessPharmacogenetics
researchProduct

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microa…

2016

Purpose: Erlotinib is a targeted agent commonly used in advanced non-small cell lung cancer (aNSCLC). However, drug-related skin toxicity often may affect the quality of life of cancer patients and lead to treatment discontinuation. Genetic polymorphisms in drug transporters and metabolizing enzymes play a major role in the interindividual variability in terms of efficacy and toxicity of erlotinib treatment. The aim of our study was to identify genetic determinants in adsorption, distribution, metabolism, and excretion genes influencing skin rash (SR) by the novel drug-metabolizing enzyme and transporter (DMET) microarray Affymetrix platform in aNSCLC patients. Methods: In a retrospective s…

0301 basic medicineOncologyMaleCancer ResearchLung Neoplasmsgenetic structuresMicroarrayPharmacologyToxicologySkin rash.0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungGenotypePharmacology (medical)Erlotinib HydrochlorideCholecalciferolOligonucleotide Array Sequence AnalysisSkin rashMiddle AgedOncologyErlotinib030220 oncology & carcinogenesisFemaleErlotinibDrug Eruptionsmedicine.drugmedicine.medical_specialtyGenotypeSingle-nucleotide polymorphismAntineoplastic AgentsPolymorphism Single Nucleotide03 medical and health sciencesErlotinib HydrochlorideInternal medicinemedicineHumansLung cancerAgedRetrospective StudiesPharmacology25-Hydroxyvitamin D3 1-alpha-HydroxylaseInflammationbusiness.industryMicroarray analysis techniquesCancerSingle nucleotide polymorphismsmedicine.diseaseSingle nucleotide polymorphism030104 developmental biologyDMETQuality of Lifebusiness
researchProduct

Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma

2020

Contains fulltext : 235640.pdf (Publisher’s version ) (Closed access) Genome-wide association studies (GWAS) of esophageal adenocarcinoma (EAC) and its precursor, Barrett's esophagus (BE), have uncovered significant genetic components of risk, but most heritability remains unexplained. Targeted assessment of genetic variation in biologically relevant pathways using novel analytical approaches may identify missed susceptibility signals. Central obesity, a key BE/EAC risk factor, is linked to systemic inflammation, altered hormonal signaling and insulin-like growth factor (IGF) axis dysfunction. Here, we assessed IGF-related genetic variation and risk of BE and EAC. Principal component analys…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyEsophageal NeoplasmsMedizinSingle-nucleotide polymorphismGenome-wide association studyBiologyAdenocarcinomaPolymorphism Single NucleotideReceptor IGF Type 103 medical and health sciencesBarrett Esophagus0302 clinical medicineRisk FactorsSomatomedinsInternal medicineGenetic variationmedicineBiomarkers TumorSNPHumansGenetic Predisposition to DiseaseRisk factorGerm-Line MutationCancer Biomarkers and Molecular EpidemiologyInsulin-like growth factor 1 receptorGenetic associationAgedGeneral MedicineMiddle Agedmedicine.diseaseRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biology030220 oncology & carcinogenesisBarrett's esophagusFemaleHuman medicineCarrier ProteinsGenome-Wide Association StudySignal TransductionCarcinogenesis
researchProduct

Association study of MMP8 gene in osteoarthritis.

2016

Objectives: Osteoarthritis (OA) is a joint disease common in the elderly. There is a prior functional evidence for different matrix metalloproteinases (MMPs), such as MMP8 and MMP9, having a role in the breakdown of cartilage extracellular matrix in OA. Thus, we analyzed whether the common genetic variants of MMP8 and MMP9 contribute to the risk of OA. Materials and methods: In total, 13 common tagging single-nucleotide polymorphisms (SNPs) were studied in a discovery knee OA cohort of 185 cases and 895 controls. For validation, two knee OA replication cohorts and two hand OA replication cohorts were studied (altogether 1369 OA cases, 4445 controls in the five cohorts). The chi(2) test for …

0301 basic medicineOncologyMaleLinkage disequilibriumLINKAGE DISEQUILIBRIUMMATRIX METALLOPROTEINASESOsteoarthritisSUSCEPTIBILITYBioinformaticsMMP8BiochemistryOrthopedics and Sports MedicineIN-VIVOta3141Middle AgedOsteoarthritis Knee3142 Public health care science environmental and occupational healthmedicine.anatomical_structureMatrix Metalloproteinase 8CohortFemaleEXPRESSIONAdultmedicine.medical_specialtySingle-nucleotide polymorphismKNEE OSTEOARTHRITISta3111Polymorphism Single NucleotideAssociationANKLE JOINTS03 medical and health sciencesRheumatologyInternal medicinemedicineSNPHumansgeneMolecular BiologyGeneAgedbusiness.industryCartilageta1184Cell BiologyARTICULAR-CARTILAGEmedicine.diseaseosteoarthritis030104 developmental biologyWIDE STATISTICAL SIGNIFICANCENEUTROPHIL COLLAGENASE3111 BiomedicinebusinessConnective tissue research
researchProduct

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and pac…

2018

Summary Purpose To investigate the safety and clinical activity of comprehensive human epidermal growth factor receptor (HER) family receptor inhibition using lumretuzumab (anti-HER3) and pertuzumab (anti-HER2) in combination with paclitaxel in patients with metastatic breast cancer (MBC). Methods This phase Ib study enrolled 35 MBC patients (first line or higher) with HER3-positive and HER2-low (immunohistochemistry 1+ to 2+ and in-situ hybridization negative) tumors. Patients received lumretuzumab (1000 mg in Cohort 1; 500 mg in Cohorts 2 and 3) plus pertuzumab (840 mg loading dose [LD] followed by 420 mg in Cohorts 1 and 2; 420 mg without LD in Cohort 3) every 3 weeks, plus paclitaxel (8…

0301 basic medicineOncologyMaleReceptor ErbB-3Receptor ErbB-2Medizinchemistry.chemical_compound0302 clinical medicineErbB3Phase I StudiesAntineoplastic Combined Chemotherapy ProtocolsMedicinePharmacology (medical)skin and connective tissue diseasesMiddle AgedMetastatic breast cancerMetastatic breast cancerDiarrheaOncologyPaclitaxel030220 oncology & carcinogenesisMarcadors bioquímicsCohortFemalePertuzumabmedicine.symptommedicine.drugAdultDiarrheamedicine.medical_specialtyLoperamidePaclitaxelMama -- Càncer -- TractamentAntineoplastic AgentsBreast NeoplasmsHypokalemiaAntibodies Monoclonal HumanizedLoading dosePolymorphism Single Nucleotide03 medical and health sciencesPhase IHuman epidermal growth factor receptor 3 (HER3)Internal medicineHumansAgedPharmacologyPertuzumabbusiness.industryBiomarkerLumretuzumabmedicine.disease030104 developmental biologychemistryHuman epidermal growth factor receptor 2 (HER2)businessHeregulin (HRG)
researchProduct

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

2016

// Aurelie Bertaut 1 , Caroline Truntzer 2 , Rachid Madkouri 3 , Coureche Guillaume Kaderbhai 4 , Valentin Derangere 5 , Julie Vincent 4 , Bruno Chauffert 6 , Marie Helene Aubriot-Lorton 7 , Wahlid Farah 3 , Klaus Luc Mourier 3 , Romain Boidot 5,8 and Francois Ghiringhelli 4,5,8,9 1 Biostatistics unit Georges Francois Leclerc Cancer Center, Dijon, France 2 CLIPP, Research Center, University of Burgundy, Dijon, France 3 Department of Neurosurgery, CHU, Dijon, France 4 Department of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon, France 5 Platform of Transfer in Cancer Biology Genetic and histology, Georges Francois Leclerc Cancer Center, Dijon, France 6 Department of Medical…

0301 basic medicineOncologyMaleVascular Endothelial Growth Factor Agenetic structuresNeutrophilsmedicine.medical_treatmentAngiogenesis InhibitorsBiomarkers Pharmacological[ SDV.CAN ] Life Sciences [q-bio]/CancerLeukocyte Count0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorEndothelial Growth-Factorprognostic factorNeoadjuvant therapyRandomized Controlled Trials as TopicNeovascularization PathologicBrain NeoplasmsColony-Stimulating FactorAge FactorsChemoradiotherapyMiddle AgedPrognosisNeoadjuvant Therapy3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisTo-Lymphocyte RatioAbsolute neutrophil countFemalemedicine.drugmedicine.medical_specialtyBevacizumabMalignant Glioma[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologybevacizumabDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPretreatment NeutrophilKarnofsky Performance StatusSingle-Agent BevacizumabRetrospective StudiesNewly-Diagnosed GlioblastomaRecurrent Glioblastomabusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyGene Expression ProfilingglioblastomaCancerRetrospective cohort studyLomustinemedicine.diseasePhase-Ii Trialeye diseasesSurgeryIrinotecan030104 developmental biologyprognosistic factorBrain-Tumorssense organsClinical Research PaperNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

Short telomere length is associated with impaired cognitive performance in European ancestry cohorts

2017

AbstractThe association between telomere length (TL) dynamics on cognitive performance over the life-course is not well understood. This study meta-analyses observational and causal associations between TL and six cognitive traits, with stratifications on APOE genotype, in a Mendelian Randomization (MR) framework. Twelve European cohorts (N=17 052; mean age=59.2±8.8 years) provided results for associations between qPCR-measured TL (T/S-ratio scale) and general cognitive function, mini-mental state exam (MMSE), processing speed by digit symbol substitution test (DSST), visuospatial functioning, memory and executive functioning (STROOP). In addition, a genetic risk score (GRS) for TL includin…

0301 basic medicineOncologycognitionNetherlands Twin Register (NTR)Psychometricsgenetic associationgenotypepolymerase chain reactionStatistics as TopicNeuropsychological Testsgenetic riskDISEASE3124 Neurology and psychiatryCohort Studies0302 clinical medicinesingle nucleotide polymorphismcognitive defectYOUNG-ADULTSgenetic variabilitytelomere lengthMedicineGWAScognitive performanceta515depth perceptionNetherlandsRISKlearningmedicine.diagnostic_testdigit symbol substitution testquantitative analysisDEMENTIAGenetic Carrier ScreeningadultarticleMini Mental State ExaminationCognitionta3142episodic memoryznf208 geneMiddle AgedTelomereapolipoprotein E4cohort analysisrtel1 genePsychiatry and Mental healthPROCESSING SPEEDacyp2 genefemaleancestry groupMENDELIAN RANDOMIZATIONOriginal ArticleClinical psychologymedicine.medical_specialtytert genePsychometricsMendelian randomization analysisgenetic risk scoreWhite People03 medical and health sciencesCellular and Molecular NeurosciencemaleInternal medicineMendelian randomizationpleiotropyJournal Article/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_HumansCognitive DysfunctionEffects of sleep deprivation on cognitive performancehumangeneBiological PsychiatryMETAANALYSISAgedterc geneStroop testMini–Mental State Examinationgenome-wide association studyIDENTIFICATIONPsykologi (exklusive tillämpad psykologi)business.industryMORTALITYobfc1 genemajor clinical studyConfidence intervalPsychology (excluding Applied Psychology)030104 developmental biologyexecutive functionDigit symbol substitution testnaf1 geneobservational studybusiness030217 neurology & neurosurgeryStroop effect
researchProduct

Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

2015

Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

0301 basic medicineOncologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BPolymorphism Single Nucleotide03 medical and health sciencesRemission induction0302 clinical medicinehemic and lymphatic diseasesInternal medicinemental disordersGeneticsOverall survivalHumansMedicineSurvival ratePharmacologybusiness.industryRemission InductionComplete remissionMyeloid leukemiaSurvival RateLeukemia Myeloid Acute030104 developmental biology030220 oncology & carcinogenesisMeta-analysisMolecular MedicinebusinessThe Pharmacogenomics Journal
researchProduct